Registration Statement
Opendoor (OPEN) Omissions About Algorithm Securities Class Action
Opendoor Technologies, Inc. was formed via a merger to operate a digital platform for flipping residential real estate. Unfortunately, the algorithm it was using to make its offers for homes was not adequate. The complaint for this securities class action alleges that the offering documents filed for the merger “were negligently prepared” and that they Read more
Bristol-Myers Squibb (BMY) Delay of Drug Approval Securities Class Action
Bristol-Myers Squibb Co. filed an S-4 Registration Statement for its November 2019 acquisition of Celgene Corporation. The complaint for this class action alleges that this S-4 contained untrue statements and omitted important information, because it did not disclose that Bristol-Myers was deliberately slow-walking approval of a drug. The slowdown would mean that certain milestones in Read more
CannTrust Securities False Statements Settlement
CannTrust Holdings, Inc. and other parties are settling class actions in Canada and the US alleging the company made false and misleading statements in its offering documents, about its compliance with cannabis regulations and due to an alleged scheme to increase its cannabis production. The complaint alleged that the statements caused the price of CannTrust’s Read more
United States Oil Fund Investment Losses Investigation
Did you lose a large amount of money on your investment with the exchange-traded fund (ETF) United States Oil Fund, LP (USO)? Do your losses on this fund add up to $250,000 or more? We’re investigating whether certain statements made by USO in its March 2020 registration statement might have been false or misleading, giving Read more
KemPharm Did Not Prove Apadaz to Be Abuse-Deterrent Securities Class Action
This securities class action alleges that KemPharm should have considered Food and Drug Administration (FDA) guidance when designing studies for its lead product candidate, an opioid painkiller the company hoped would be labeled as abuse-deterrent. Ignoring those guidelines, the complaint says, made it unlikely that the drug would get the approval it needed and made Read more